INT99821

From wiki-pain
Revision as of 12:42, 23 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 2001
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 20
Total Number 20
Disease Relevance 15.21
Pain Relevance 3.94

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Golgi apparatus (APP) extracellular matrix organization (APP) DNA binding (APP)
cytoplasm (APP) cytosol (APP) extracellular region (APP)
Anatomy Link Frequency
neuronal 2
brains 2
cortex 2
hippocampus 2
APP (Homo sapiens)
Pain Link Frequency Relevance Heat
Hippocampus 41 100.00 Very High Very High Very High
cytokine 40 100.00 Very High Very High Very High
Abeta 35 100.00 Very High Very High Very High
Pyramidal cell 8 100.00 Very High Very High Very High
cINOD 110 98.88 Very High Very High Very High
Eae 7 96.56 Very High Very High Very High
Inflammation 68 92.44 High High
Inflammatory mediators 2 78.52 Quite High
metalloproteinase 1 73.00 Quite High
Central nervous system 10 67.48 Quite High
Disease Link Frequency Relevance Heat
Alzheimer's Dementia 297 100.00 Very High Very High Very High
Apoptosis 39 100.00 Very High Very High Very High
Lyme Neuroborreliosis 106 99.92 Very High Very High Very High
Facial Paralysis 16 99.84 Very High Very High Very High
Cognitive Disorder 68 99.64 Very High Very High Very High
Acute Disease 4 99.28 Very High Very High Very High
Stress 176 99.18 Very High Very High Very High
Targeted Disruption 83 99.12 Very High Very High Very High
Disease 686 97.20 Very High Very High Very High
Autism 2 97.12 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Higher levels of secreted APP and nonamyloidogenic secreted APP and lower levels of A?
Negative_regulation (secreted) of Gene_expression (levels) of APP
1) Confidence 0.42 Published 2007 Journal Acta Neuropathol Section Body Doc Link PMC1824787 Disease Relevance 0.62 Pain Relevance 0
A 30% decrease in cellular levels of APP-CTF?
Negative_regulation (decrease) of Gene_expression (levels) of APP
2) Confidence 0.42 Published 2008 Journal Mol Neurodegener Section Body Doc Link PMC2323375 Disease Relevance 0 Pain Relevance 0
deposition in the hippocampus of the APPswe/PS1?
Negative_regulation (deposition) of Gene_expression (hippocampus) of APP in hippocampus associated with hippocampus
3) Confidence 0.41 Published 2010 Journal International Journal of Alzheimer's Disease Section Body Doc Link PMC2952897 Disease Relevance 0.81 Pain Relevance 0.09
in the brains of each group to determine whether any change in the amount or solubility of peptide occurred while APPswe/ind expression was suppressed.
Negative_regulation (suppressed) of Gene_expression (expression) of APP in brains
4) Confidence 0.41 Published 2005 Journal PLoS Medicine Section Body Doc Link PMC1283364 Disease Relevance 0.08 Pain Relevance 0
by decreasing the protein levels of APP and C99, suggesting that excessive A?
Negative_regulation (decreasing) of Gene_expression (levels) of APP
5) Confidence 0.41 Published 2008 Journal The Journal of Biological Chemistry Section Body Doc Link PMC2427353 Disease Relevance 0.63 Pain Relevance 0.03
peptides are seen, such as facial palsy LNB, a decreased APP expression is unlikely.
Negative_regulation (decreased) of Gene_expression (expression) of APP associated with lyme neuroborreliosis and facial paralysis
6) Confidence 0.39 Published 2010 Journal BMC Neurol Section Body Doc Link PMC2902447 Disease Relevance 0.73 Pain Relevance 0
We report an association of cerebral amyloid metabolism with LNB, with decreased CSF levels of soluble APP-fragments in the acute disease stage.
Negative_regulation (decreased) of Gene_expression (levels) of APP associated with acute disease, lyme neuroborreliosis and alzheimer's dementia
7) Confidence 0.39 Published 2010 Journal BMC Neurol Section Body Doc Link PMC2902447 Disease Relevance 1.52 Pain Relevance 0.12
Trying to decrease the production of Amyloid beta (Abeta) has been envisaged as a promising approach to prevent neurodegeneration in Alzheimer's disease (AD).
Negative_regulation (decrease) of Gene_expression (production) of Abeta associated with alzheimer's dementia, disease and abeta
8) Confidence 0.38 Published 2001 Journal Neurobiol. Dis. Section Abstract Doc Link 11741404 Disease Relevance 0.76 Pain Relevance 0.35
Higher levels of secreted APP and nonamyloidogenic secreted APP and lower levels of A?
Negative_regulation (secreted) of Gene_expression (levels) of APP
9) Confidence 0.37 Published 2007 Journal Acta Neuropathol Section Body Doc Link PMC1824787 Disease Relevance 0.62 Pain Relevance 0
This suggests that H2O2 treatment leads to a shift in APP processing from the ?
Negative_regulation (shift) of Gene_expression (processing) of APP
10) Confidence 0.36 Published 2008 Journal The Journal of Biological Chemistry Section Body Doc Link PMC2427353 Disease Relevance 0.61 Pain Relevance 0.03
Figures 1, 2 and 3 schematically summarize APP metabolism, A?
Negative_regulation (summarize) of Gene_expression (metabolism) of APP
11) Confidence 0.35 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2656296 Disease Relevance 0.82 Pain Relevance 0.04
The reduction in the production of Abeta by ibuprofen was presumably due to a decreased production of betaAPP, which in contrast to the control proteins M2 pyruvate kinase, beta-tubulin and the cytokine inducible ICAM-1 was detected at low concentration in ibuprofen treated cells.
Negative_regulation (reduction) of Gene_expression (production) of Abeta associated with cytokine and abeta
12) Confidence 0.33 Published 2001 Journal Neurobiol. Dis. Section Abstract Doc Link 11741404 Disease Relevance 0.66 Pain Relevance 0.72
This study provides an important structural clue for the rational design of drugs to inhibit processing of APP at the ?
Negative_regulation (inhibit) of Gene_expression (processing) of APP
13) Confidence 0.31 Published 2008 Journal Mol Neurodegener Section Abstract Doc Link PMC2405781 Disease Relevance 0 Pain Relevance 0.08
Oxidative stress inducers are believed to participate in apoptosis, APP processing, A?
Negative_regulation (apoptosis) of Gene_expression (processing) of APP associated with stress and apoptosis
14) Confidence 0.29 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2644820 Disease Relevance 1.50 Pain Relevance 0
Trying to decrease the production of Amyloid beta (Abeta) has been envisaged as a promising approach to prevent neurodegeneration in Alzheimer's disease (AD).
Negative_regulation (decrease) of Gene_expression (production) of Amyloid beta associated with alzheimer's dementia, disease and abeta
15) Confidence 0.27 Published 2001 Journal Neurobiol. Dis. Section Abstract Doc Link 11741404 Disease Relevance 0.75 Pain Relevance 0.35
Ibuprofen decreases cytokine-induced amyloid beta production in neuronal cells.
Negative_regulation (decreases) of Gene_expression (production) of amyloid beta in neuronal associated with alzheimer's dementia and cytokine
16) Confidence 0.24 Published 2001 Journal Neurobiol. Dis. Section Title Doc Link 11741404 Disease Relevance 0.87 Pain Relevance 0.74
-amyloid precursor protein production, degeneration of hippocampal CA3 pyramidal neurons (Hauss-Wegrzyniak et al., 1998), a loss of pyramidal cells in entorhinal cortex (Hauss-Wegrzyniak et al., 2002), loss of basal forebrain cholinergic neurons (Willard et al., 2000), decreased spatial memory performance (Hauss-Wegrzyniak et al., 2000a), and no recovery of memory function over time (Hauss-Wegrzyniak et al., 2000b).
Negative_regulation (decreased) of Gene_expression (production) of amyloid precursor protein in cortex associated with cognitive disorder, pyramidal cell and alzheimer's dementia
17) Confidence 0.20 Published 2010 Journal Frontiers in Aging Neuroscience Section Body Doc Link PMC2944647 Disease Relevance 1.47 Pain Relevance 0.67
A subset of NSAIDs, including flurbiprofen, has been shown to selectively inhibit the production of beta-amyloid(1-42) (Abeta42), independently from their cyclooxygenase (COX) inhibiting activity.
Negative_regulation (inhibit) of Gene_expression (production) of beta-amyloid associated with alzheimer's dementia and cinod
18) Confidence 0.13 Published 2007 Journal Pharmacol. Res. Section Abstract Doc Link 17292621 Disease Relevance 0.42 Pain Relevance 0.33
The most frequent directions are therapies aiming to decrease the production or the deposition of beta-amyloid peptide.
Negative_regulation (decrease) of Gene_expression (production) of beta-amyloid peptide associated with alzheimer's dementia
19) Confidence 0.04 Published 2009 Journal Neuropsychopharmacol Hung Section Abstract Doc Link 19731816 Disease Relevance 1.48 Pain Relevance 0
The biological mechanism of this protection is not completely understood and may involve inhibition of COX activity, inhibition of beta-amyloid(1-42) (Abeta42) production and aggregation, inhibition of beta-secretase activity, activation of PPAR-gamma or stimulation of neurotrophin synthesis.
Negative_regulation (inhibition) of Gene_expression (production) of beta-amyloid associated with alzheimer's dementia
20) Confidence 0.00 Published 2009 Journal Expert Opin Investig Drugs Section Abstract Doc Link 19589092 Disease Relevance 0.89 Pain Relevance 0.39

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox